DK1335725T3 - Anvendelse af CCI-779 som et antineoplastisk middel - Google Patents

Anvendelse af CCI-779 som et antineoplastisk middel

Info

Publication number: DK1335725T3
Authority: DK; Denmark
Prior art keywords: cci; antineoplastic agent; antineoplastic; agent
Prior art date: 2000-11-15

Application number

DK01996175T

Other languages

English (en)

Inventor

Gary Dukart

James Joseph Gibbons Jr

Lisa Anne Speicher

Carolyn Mary Discafani-Marro

Philip Frost

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-15

Filing date

2001-11-13

Publication date

2008-06-30

2001-11-13 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-06-30 Application granted granted Critical

2008-06-30 Publication of DK1335725T3 publication Critical patent/DK1335725T3/da

Links

CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
229940034982 antineoplastic agent Drugs 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
229960000235 temsirolimus Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK01996175T 2000-11-15 2001-11-13 Anvendelse af CCI-779 som et antineoplastisk middel DK1335725T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24907700P	2000-11-15	2000-11-15
PCT/US2001/047324 WO2002040000A2 (en)	2000-11-15	2001-11-13	Use of cci-779 as an antineoplastic agent

Publications (1)

Publication Number	Publication Date
DK1335725T3 true DK1335725T3 (da)	2008-06-30

Family

ID=22941961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01996175T DK1335725T3 (da)	2000-11-15	2001-11-13	Anvendelse af CCI-779 som et antineoplastisk middel

Country Status (27)

Country	Link
US (3)	US20020091137A1 (da)
EP (1)	EP1335725B1 (da)
JP (4)	JP4472251B2 (da)
KR (1)	KR100827942B1 (da)
CN (2)	CN102058588A (da)
AR (1)	AR031341A1 (da)
AT (1)	ATE393629T1 (da)
AU (2)	AU2731302A (da)
BR (1)	BR0115323A (da)
CA (1)	CA2429020C (da)
CY (1)	CY1108109T1 (da)
DE (1)	DE60133831T2 (da)
DK (1)	DK1335725T3 (da)
EA (1)	EA007096B1 (da)
ES (1)	ES2305134T3 (da)
HU (1)	HUP0400521A3 (da)
IL (2)	IL155871A0 (da)
MX (1)	MXPA03004192A (da)
NO (1)	NO20032181L (da)
NZ (1)	NZ539668A (da)
PL (1)	PL207061B1 (da)
PT (1)	PT1335725E (da)
SG (1)	SG148031A1 (da)
SI (1)	SI1335725T1 (da)
TW (1)	TWI286074B (da)
WO (1)	WO2002040000A2 (da)
ZA (1)	ZA200304603B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT2762140T (lt)	2001-02-19	2017-06-26	Novartis Ag	Solidinių smegenų navikų gydymas rapamicino dariniu
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
WO2002098416A2 (en) *	2001-06-01	2002-12-12	Wyeth	Antineoplastic combinations
US20020198137A1 (en) *	2001-06-01	2002-12-26	Wyeth	Antineoplastic combinations
BR0307544A (pt) *	2002-02-01	2004-12-07	Ariad Gene Therapeutics Inc	Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
JP2005531391A (ja) *	2002-06-27	2005-10-20	微創医療器械（上海）有限公司	薬剤放出ステント
AU2003254168A1 (en)	2002-07-30	2004-02-16	Wyeth	Parenteral formulations containing a rapamycin hydroxyester
DE60324609D1 (de) *	2002-09-17	2008-12-18	Wyeth Corp	GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
AU2003298689A1 (en)	2002-11-21	2004-06-18	Wyeth	Methods for diagnosing rcc and other solid tumors
US20050287532A9 (en) *	2003-02-11	2005-12-29	Burczynski Michael E	Methods for monitoring drug activities in vivo
US7643943B2 (en)	2003-02-11	2010-01-05	Wyeth Llc	Methods for monitoring drug activities in vivo
WO2004072265A2 (en) *	2003-02-11	2004-08-26	Wyeth	Methods for monitoring drug activities in vivo
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20040258662A1 (en) *	2003-04-22	2004-12-23	Wyeth	Antineoplastic agents
CA2523798A1 (en) *	2003-04-29	2004-11-11	Wyeth	Methods for prognosis and treatment of solid tumors
MXPA05013865A (es) *	2003-07-25	2006-02-28	Wyeth Corp	Formulaciones liofilizadas de cci-779.
AR046194A1 (es) *	2003-11-04	2005-11-30	Mayo Foundation	Metodo de tratamiento del linfoma de celulas del manto
DK1701698T3 (da) *	2004-01-08	2008-05-05	Wyeth Corp	Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
AR047988A1 (es) *	2004-03-11	2006-03-15	Wyeth Corp	Combinaciones antineoplásicas de cci-779 y rituximab
CN108421044A (zh)	2005-02-03	2018-08-21	综合医院公司	治疗吉非替尼耐药性癌症的方法
CA2596392A1 (en) *	2005-02-15	2006-08-24	Wyeth	Orally bioavailable cci-779 tablet formulations
BRPI0618042A2 (pt)	2005-11-04	2011-08-16	Wyeth Corp	usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
EP2275103B1 (en) *	2005-11-21	2014-04-23	Novartis AG	mTOR inhibitors in the treatment of endocrine tumors
EP1962819A1 (en) *	2005-12-20	2008-09-03	Wyeth	Control of cci-779 dosage form stability through control of drug substance impurities
DE102006011507A1 (de) *	2006-03-14	2007-09-20	Lts Lohmann Therapie-Systeme Ag	Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) *	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched temsirolimus
CA2709413C (en) *	2007-10-03	2017-09-12	Genesis Technical Systems Corp.	Dynamic, asymmetric rings
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2278966B1 (en)	2008-03-21	2019-10-09	The University of Chicago	Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) *	2008-03-21	2016-09-15	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
CN102641270A (zh)	2008-06-17	2012-08-22	惠氏有限责任公司	含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en)	2008-08-04	2014-03-11	Wyeth Llc	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en)	2009-04-06	2024-01-01	Wyeth Llc	Regimen comprising neratinib for the treatment of cancer
US8716307B2 (en) *	2009-05-13	2014-05-06	The Trustees Of The University Of Pennsylvania	Combination antineoplastic therapy
JP2013527223A (ja) *	2010-06-02	2013-06-27	フレゼニウス・カビ・オンコロジー・リミテッド	ラパマイシンエステルの安定な医薬組成物
US9745941B2 (en) *	2014-04-29	2017-08-29	Ford Global Technologies, Llc	Tunable starter resistor
KR101965319B1 (ko) *	2015-08-24	2019-04-04	샨시 야바오 헬스 프로덕츠 컴퍼니 리미티드	항종양 약물 제조에서의 다이하이드록시아세톤의 용도
CN111110676A (zh) *	2020-03-07	2020-05-08	天津医科大学总医院	阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US5206018A (en)	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
BE877700A (fr) *	1978-11-03	1980-01-14	Ayerst Mckenna & Harrison	Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en)	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US4401653A (en)	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en)	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5321009A (en)	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
SG43072A1 (en)	1991-06-18	1997-10-17	American Home Prod	Method of treating adult t-cell leukemia/lymphoma
IL102414A (en)	1991-07-25	1996-08-04	Univ Louisville Res Found	Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en)	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5561138A (en)	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en)	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
ES2228932T3 (es)	2000-08-11	2005-04-16	Wyeth	Procedimiento de tratamiento del carcinoma positivo de estrogenos.
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en)	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en)	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569

2001
- 2001-11-05 TW TW090127415A patent/TWI286074B/zh not_active IP Right Cessation
- 2001-11-13 MX MXPA03004192A patent/MXPA03004192A/es active IP Right Grant
- 2001-11-13 CN CN2010101653331A patent/CN102058588A/zh active Pending
- 2001-11-13 AU AU2731302A patent/AU2731302A/xx active Pending
- 2001-11-13 DE DE60133831T patent/DE60133831T2/de not_active Expired - Lifetime
- 2001-11-13 US US10/010,584 patent/US20020091137A1/en not_active Abandoned
- 2001-11-13 SG SG200505237-8A patent/SG148031A1/en unknown
- 2001-11-13 JP JP2002542375A patent/JP4472251B2/ja not_active Expired - Lifetime
- 2001-11-13 KR KR1020037006542A patent/KR100827942B1/ko not_active Expired - Lifetime
- 2001-11-13 EA EA200300566A patent/EA007096B1/ru not_active IP Right Cessation
- 2001-11-13 BR BR0115323-4A patent/BR0115323A/pt not_active Application Discontinuation
- 2001-11-13 EP EP01996175A patent/EP1335725B1/en not_active Expired - Lifetime
- 2001-11-13 SI SI200130829T patent/SI1335725T1/sl unknown
- 2001-11-13 PT PT01996175T patent/PT1335725E/pt unknown
- 2001-11-13 DK DK01996175T patent/DK1335725T3/da active
- 2001-11-13 IL IL15587101A patent/IL155871A0/xx unknown
- 2001-11-13 PL PL362740A patent/PL207061B1/pl unknown
- 2001-11-13 AT AT01996175T patent/ATE393629T1/de not_active IP Right Cessation
- 2001-11-13 ES ES01996175T patent/ES2305134T3/es not_active Expired - Lifetime
- 2001-11-13 NZ NZ539668A patent/NZ539668A/en unknown
- 2001-11-13 HU HU0400521A patent/HUP0400521A3/hu unknown
- 2001-11-13 CA CA002429020A patent/CA2429020C/en not_active Expired - Lifetime
- 2001-11-13 WO PCT/US2001/047324 patent/WO2002040000A2/en not_active Ceased
- 2001-11-13 CN CNA018189261A patent/CN1678312A/zh active Pending
- 2001-11-14 AR ARP010105310A patent/AR031341A1/es unknown
2003
- 2003-02-26 US US10/374,644 patent/US7189735B2/en not_active Expired - Lifetime
- 2003-05-12 IL IL155871A patent/IL155871A/en active IP Right Grant
- 2003-05-14 NO NO20032181A patent/NO20032181L/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304603A patent/ZA200304603B/en unknown
2007
- 2007-02-01 US US11/701,109 patent/US7781446B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007201324A patent/AU2007201324B2/en not_active Expired
2008
- 2008-06-02 CY CY20081100573T patent/CY1108109T1/el unknown
2009
- 2009-09-18 JP JP2009216883A patent/JP2010018620A/ja active Pending
2014
- 2014-01-15 JP JP2014005231A patent/JP2014088430A/ja not_active Withdrawn
2015
- 2015-12-10 JP JP2015241449A patent/JP2016094444A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CY1108109T1 (el)	2014-02-12
PL362740A1 (en)	2004-11-02
WO2002040000A3 (en)	2002-09-06
DE60133831T2 (de)	2009-05-20
SG148031A1 (en)	2008-12-31
JP2004517065A (ja)	2004-06-10
EP1335725A2 (en)	2003-08-20
DE60133831D1 (de)	2008-06-12
US7189735B2 (en)	2007-03-13
JP4472251B2 (ja)	2010-06-02
ES2305134T3 (es)	2008-11-01
CN102058588A (zh)	2011-05-18
ATE393629T1 (de)	2008-05-15
AU2007201324B2 (en)	2010-11-18
EP1335725B1 (en)	2008-04-30
ZA200304603B (en)	2004-09-13
PL207061B1 (pl)	2010-10-29
NO20032181D0 (no)	2003-05-14
EA007096B1 (ru)	2006-06-30
US20030153593A1 (en)	2003-08-14
JP2010018620A (ja)	2010-01-28
TWI286074B (en)	2007-09-01
AU2731302A (en)	2002-05-27
IL155871A0 (en)	2003-12-23
US7781446B2 (en)	2010-08-24
AR031341A1 (es)	2003-09-17
CA2429020C (en)	2009-05-26
US20070142425A1 (en)	2007-06-21
MXPA03004192A (es)	2003-09-22
CA2429020A1 (en)	2002-05-23
JP2016094444A (ja)	2016-05-26
NZ539668A (en)	2007-06-29
HUP0400521A3 (en)	2007-05-29
NO20032181L (no)	2003-05-14
US20020091137A1 (en)	2002-07-11
WO2002040000A2 (en)	2002-05-23
HUP0400521A2 (hu)	2004-06-28
CN1678312A (zh)	2005-10-05
JP2014088430A (ja)	2014-05-15
BR0115323A (pt)	2004-02-17
SI1335725T1 (sl)	2008-08-31
KR100827942B1 (ko)	2008-05-13
EA200300566A1 (ru)	2003-10-30
KR20040029309A (ko)	2004-04-06
AU2007201324A1 (en)	2007-04-19
PT1335725E (pt)	2008-06-19
HK1058008A1 (en)	2004-04-30
IL155871A (en)	2012-03-29

Publication	Publication Date	Title
NO20032181D0 (no)	2003-05-14	Anvendelse av CCI-779 som et antineoplastisk middel
DK1608407T3 (da)	2006-12-04	Dispergébar formulering af et antiinflammatorisk middel
NO20030929D0 (no)	2003-02-27	Guanidinobenzamider som MC4-R agonister
PT1399127E (pt)	2005-07-29	Formulacoes de olopatadina para administracao topica
NO20042955L (no)	2004-07-12	Substituerte fenylaftalener som estrogene midler
NO20030138D0 (no)	2003-01-10	Lipidrikt plakkinnkapslende middel
DK1438306T3 (da)	2014-06-23	Derivater af UK-2A
NL300343I1 (nl)	2008-06-02	6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1, 4-dieen-17-carbothionzuur-s-fluormethylester alseen ontstekingremmend middel
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
NO20032531D0 (no)	2003-06-04	Tetralon-derivater som antitumormidler
NO20026037L (no)	2003-02-06	Sötvareprodukt som inneholder aktive bestanddeler
NO20014412D0 (no)	2001-09-11	Forbindelser nyttige som anti-inflammatoriske midler
ATE306928T1 (de)	2005-11-15	Fulvestrant formulierung
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
DK1073416T3 (da)	2009-03-09	Anvendelse af NO som anti-inflammatorisk middel
NO20033618D0 (no)	2003-08-14	Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20041316L (no)	2004-03-30	Tiofen- og tiazoisulfonamider som antineoplastiske midler
DK1337521T3 (da)	2007-01-29	Salte af en isothiasol-4-carboxamid og deres anvendelse som antihyperproliferationsmiddel
NO20040775L (no)	2004-02-17	Oftalmisk sammensetning som innbefatter et askomycin
NO20054790D0 (no)	2005-10-18	Anvendelse av B7-113 som et immunoregulatorisk middel
ATE459598T1 (de)	2010-03-15	Sulfonamidderivate
NO20021959D0 (no)	2002-04-25	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
DK1268482T3 (da)	2003-12-22	Pyranoindoler til behandling af glaukom
AR028398A1 (es)	2003-05-07	Ciclipostinas, procedimiento para su preparacion, y utilizacion de las mismas
NO20031239D0 (no)	2003-03-18	1-amino-alkylsykloheksaner som trypanocidale midler